Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Alroughani, Raed, Huppke, Peter, Mazurkiewicz-Beldzinska, Maria, Blaschek, Astrid, Valis, Martin, Aaen, Gregory, Pultz, Joe, Peng, Xiaomei, Beynon, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812971/
https://www.ncbi.nlm.nih.gov/pubmed/33473248
http://dx.doi.org/10.3389/fneur.2020.606418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812971/
https://www.ncbi.nlm.nih.gov/pubmed/33473248
http://dx.doi.org/10.3389/fneur.2020.606418

Ejemplares similares